R&D FORMULATION DEVELOPMENT
More Reyra operates a state-of-the -art Formulation Development Laboratory focused on developing and launching sophisticated generic formulations for global markets. certified by DSIR (Department Science & Industrial Research) the laboratory is staffed by a research team of seasoned scientists with extensive expertise in creating safe, effective, and compliant complex drug products that meet stringent global regulatory standards.
Some of the primary activities in R&D include:
Pre-formulation Development: The goal is to gather data essential for developing bioavailable dosage forms. This involves studying parameters such as the physicochemical properties of the drug (e.g., solubility, partition coefficient, dissolution rate, stability, solid-state analysis including polymorphs and particle size), establishing kinetic rate profiles, and conducting excipient compatibility studies.
Formulation Development: The R&D department has successfully developed products in the areas of immunosuppressants and oncology. It possesses the expertise and infrastructure to formulate a diverse range of dosage forms, both sterile and non-sterile, including solid orals (tablets and capsules), oral liquids, oral suspensions, lyophilized formulations, and sterile injectables.